• Publications
  • Influence

Claim Your Author Page
Ensure your research is discoverable on Semantic Scholar. Claiming your author page allows you to personalize the information displayed and manage your publications. Semantic Scholar automatically creates author pages based on data aggregated from public sources and our publisher partners.
  • Thomas Philip, Cesare Guglielmi, +7 authors Jean Luc Harousseau
  • Medicine
  • The New England journal of medicine
  • 1995 (First Publication: 7 December 1995)
  • BACKGROUND High-dose chemotherapy followed by autologous bone marrow transplantation is a therapeutic option for patients with chemotherapy-sensitive non-Hodgkin's lymphoma who have relapses. In thisExpand
  • Marinus H. J. van Oers, Richard Klasa, +11 authors Anton Hagenbeek
  • Medicine
  • Blood
  • 2006 (First Publication: 15 November 2006)
  • We evaluated the role of rituximab (R) both in remission induction and maintenance treatment of relapsed/resistant follicular lymphoma (FL). A total of 465 patients were randomized to induction withExpand
  • Bruce D Cheson, Sandra J. Horning, +16 authors George P. Canellos
  • Medicine
  • Journal of clinical oncology : official journal…
  • 1999 (First Publication: 1 April 1999)
  • Standardized guidelines for response assessment are needed to ensure comparability among clinical trials in non-Hodgkin's lymphomas (NHL). To achieve this, two meetings were convened among UnitedExpand
  • Marinus H.J. van Oers, Martine van Glabbeke, +8 authors Anton Hagenbeek
  • Medicine
  • Journal of clinical oncology : official journal…
  • 2010 (First Publication: 10 June 2010)
  • PURPOSE In 2006, we published the results of the European Organisation for Research and Treatment of Cancer phase III trial EORTC 20981 on the role of rituximab in remission induction and maintenanceExpand
  • Flora E van Leeuwen, Willem J. Klokman, +8 authors Berthe M. P. Aleman
  • Medicine
  • Journal of clinical oncology : official journal…
  • 2000 (First Publication: 1 February 2000)
  • PURPOSE To quantify the long-term risk of second primary cancers (SCs) in patients diagnosed with Hodgkin's disease (HD) during adolescence or young adulthood. PATIENTS AND METHODS The risk of SCsExpand
  • Maria Corinna Palanca-Wessels, Myron S. Czuczman, +18 authors Franck Morschhauser
  • Medicine
  • The Lancet. Oncology
  • 2015 (First Publication: 1 June 2015)
  • BACKGROUND Patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL) have an unfavourable prognosis with few treatment options. Polatuzumab vedotin is an antibody-drug conjugateExpand
  • Anton Hagenbeek, Ole V. Gadeberg, +14 authors John Radford
  • Medicine
  • Blood
  • 2008 (First Publication: 15 June 2008)
  • Ofatumumab is a unique monoclonal antibody that targets a distinct small loop epitope on the CD20 molecule. Preclinical data show that ofatumumab is active against B-cell lymphoma/chronic lymphocyticExpand
  • Rozemarijn S van Rijn, Elles R. Simonetti, +10 authors Saskia B. Ebeling
  • Medicine
  • Blood
  • 2003 (First Publication: 1 October 2003)
  • The safe application of new strategies for the treatment of graft-versus-host disease (GVHD) is hampered by the lack of a clinically relevant model for preclinical testing. Current models are basedExpand